Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CCR9 | P51686 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809229 | 0.89 | MCL1 (0.36) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL23809507 | 0.88 | ALDH1A1 (0.37) | KMT2AALDH1A1CCR2CCR9 | |
| SCHEMBL26581349 | 0.87 | MEN1 (0.42) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL23809200 | 0.86 | KDM4E (0.41) | KDM4EALDH1A1LMNAPKMSMN1; SMN2 | |
| SCHEMBL23809122 | 0.82 | KMT2A (0.41) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL30547759 | 0.80 | CCR2 (0.58) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL26581439 | 0.77 | CCR2 (0.39) | KMT2AMEN1LMNACCR2SMN1; SMN2 | |
| SCHEMBL26581364 | 0.77 | MCL1 (0.42) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL23809215 | 0.76 | ALDH1A1 (0.41) | KDM4EALDH1A1CCR2L3MBTL1HPGD | |
| SCHEMBL23809287 | 0.76 | GPR35 (0.38) | ALDH1A1CCR2CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | KMT2A 824/4885MEN1 3549/4885KDM4E 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.